

2 Months

Study	Country	Design		VE (95% CI)
Andrews et al., 2022 (age 19-49)	UK	TN		0.78 (0.76, 0.79)
Andrews et al., 2022 (age 50+)	UK	TN	 	0.82 (0.81, 0.83)
Ranzani et al., 2022	Brazil	MTN	 	0.34 (0.33, 0.35)
Gonzalez et al., 2022	Argentina	MTN	-	0.19 (0.17, 0.20)
			0 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)	

3 Months

